KMI169 is a potent and selective bi-substrate inhibitor of KMT9, targeting its SAM and substrate binding pockets. KMT9 monomethylates histone H4 lysine 12, regulating prostate cancer cell proliferation. KMI169 is suitable for prostate cancer research.
KMI169 is a potent and selective bi-substrate inhibitor of KMT9, targeting its SAM and substrate binding pockets. KMT9 monomethylates histone H4 lysine 12, regulating prostate cancer cell proliferation. KMI169 is suitable for prostate cancer research.
Store lyophilized at -20ºC, keep desiccated. In lyophilized form, the chemical is stable for 36 months. In solution, store at -20ºC and use within 1 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula: